{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:44:07Z","timestamp":1788410647079,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.akdh.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:54:19Z","timestamp":1682110459000},"page":"228-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1053","volume":"30","author":[{"given":"William","family":"Ackley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9961","authenticated-orcid":false,"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-0894","authenticated-orcid":false,"given":"Meyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.akdh.2023.02.002_bib1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.02.002_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"10.1053\/j.akdh.2023.02.002_bib3","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.akdh.2023.02.002_bib4","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2215\/CJN.10250620","article-title":"Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"16","author":"Torres","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2215\/CJN.17981120","article-title":"Long-term safety of tolvaptan in ADPKD: where do We Stand?","volume":"16","author":"Patel","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2023.02.002_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2022.10.004","article-title":"Much Ado about Something: the clinical Pattern of tolvaptan-associated liver injury in participants with ADPKD","volume":"81","author":"Postalcioglu","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2023.02.002_bib8","doi-asserted-by":"crossref","first-page":"p281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical Pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.akdh.2023.02.002_bib9","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol : JASN (J Am Soc Nephrol)"},{"key":"10.1053\/j.akdh.2023.02.002_bib10","series-title":"Pooled Data Analysis of the Long-Term Effect of Tolvaptan in Patients Between 56 and 65 Years With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","author":"Chebib","year":"2022"},{"issue":"8","key":"10.1053\/j.akdh.2023.02.002_bib11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD patients with Very low kidney function","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.akdh.2023.02.002_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10157-020-01988-4","article-title":"Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations","volume":"25","author":"Moriyama","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2023.02.002_bib13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term Administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2215\/CJN.13071021","article-title":"Assessing risk of progression in ADPKD","volume":"17","author":"Gordon","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2023.02.002_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2215\/CJN.08170719","article-title":"A post hoc analysis of statin Use in tolvaptan autosomal dominant polycystic kidney disease pivotal trials","volume":"15","author":"Shoaf","year":"2020","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"issue":"4","key":"10.1053\/j.akdh.2023.02.002_bib16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/cts.13017","article-title":"Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters","volume":"14","author":"Shoaf","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a Mechanistic model to evaluate Putative mechanisms of tolvaptan drug-induced liver injury and Identify patient Susceptibility Factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol Sci: an official journal of the Society of Toxicology"},{"issue":"2","key":"10.1053\/j.akdh.2023.02.002_bib18","first-page":"438","article-title":"Editor's highlight: Candidate risk Factors and mechanisms for tolvaptan-induced liver injury are Identified using a collaborative cross approach","volume":"156","author":"Mosedale","year":"2017","journal-title":"Toxicol Sci: an official journal of the Society of Toxicology"},{"issue":"3","key":"10.1053\/j.akdh.2023.02.002_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2023.02.002_bib20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical Pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials Database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"issue":"11","key":"10.1053\/j.akdh.2023.02.002_bib21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ekir.2019.09.002","article-title":"Role of liver transplantation in tolvaptan-associated acute liver failure","volume":"4","author":"Endo","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.akdh.2023.02.002_bib22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.akdh.2023.02.002_bib23","first-page":"1","article-title":"Creatine kinase elevation in autosomal dominant polycystic kidney disease patients on tolvaptan treatment","author":"Rodr\u00edguez-Espinosa","year":"2022","journal-title":"Nephron"},{"issue":"6","key":"10.1053\/j.akdh.2023.02.002_bib24","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2023.02.002_bib25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2023.02.002_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ekir.2020.03.011","article-title":"The NOCTURNE randomized trial comparing 2 tolvaptan formulations","volume":"5","author":"Perrone","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib27","doi-asserted-by":"crossref","first-page":"17666","DOI":"10.1038\/s41598-021-97113-w","article-title":"The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial","volume":"11","author":"Uchiyama","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1053\/j.akdh.2023.02.002_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2215\/CJN.11260821","article-title":"Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial","volume":"17","author":"Kramers","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.02.002_bib29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/jcm3041276","article-title":"Review of Tolvaptan's pharmacokinetic and Pharmacodynamic Properties and drug interactions","volume":"3","author":"Bhatt","year":"2014","journal-title":"J Clin Med"},{"issue":"7","key":"10.1053\/j.akdh.2023.02.002_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.34067\/KID.0007342020","article-title":"Dose-dependent effect of tolvaptan on renal Prognosis in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Akihisa","year":"2021","journal-title":"Kidney360"},{"key":"10.1053\/j.akdh.2023.02.002_bib31","series-title":"Urine osmolality (Uosm) is a reasonable marker of acute (TKV) and longer-term (eGFR) efficacy of vasopressin receptor antagonism in ADPKD: post-hoc analysis of TEMPO 3:4","author":"Ivaturi","year":"2021"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease","volume":"1","author":"Rangan","year":"2022","journal-title":"NEJM Evidence"},{"issue":"5","key":"10.1053\/j.akdh.2023.02.002_bib33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ekir.2022.02.009","article-title":"Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2023.02.002_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.kint.2020.03.022","article-title":"Tolvaptan or transplant: why wait?","volume":"98","author":"Gordon","year":"2020","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.akdh.2023.02.002_bib36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"19","key":"10.1053\/j.akdh.2023.02.002_bib37","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.akdh.2023.02.002_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during Use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label Multicenter DIPAK-1 study","volume":"40","author":"Lantinga","year":"2017","journal-title":"Drug Saf"},{"issue":"3","key":"10.1053\/j.akdh.2023.02.002_bib39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","article-title":"Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat","volume":"26","author":"Gile","year":"1995","journal-title":"Am J Kidney Dis: the official journal of the National Kidney Foundation"},{"issue":"5","key":"10.1053\/j.akdh.2023.02.002_bib40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"issue":"1","key":"10.1053\/j.akdh.2023.02.002_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2010","journal-title":"Scand J Urol Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2023.02.002_bib42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.34067\/KID.0007422020","article-title":"Examining the role of Novel CKD therapies for the ADPKD patient","volume":"2","author":"Patel","year":"2021","journal-title":"Kidney360"},{"issue":"4","key":"10.1053\/j.akdh.2023.02.002_bib43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic Reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol: CJASN"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:39:21Z","timestamp":1757432361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813923000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2949813923000307"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2023.02.002","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}